Gyre Therapeutics (GYRE) Property, Plant & Equipment (Net) Growth (3y) (2014 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Property, Plant & Equipment (Net) Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.05% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.65% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 411.50% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -3.34% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 16.78% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.66% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 19.96% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2,767.25% |
| Dec 31, 2025 | 15.87% |
| Sep 30, 2025 | 475.28% |
| Jun 30, 2025 | 422.55% |
| Mar 31, 2025 | 201.63% |
| Dec 31, 2024 | 190.91% |
| Sep 30, 2024 | 181.91% |
| Jun 30, 2024 | 225.88% |
| Mar 31, 2024 | 295.12% |
| Dec 31, 2023 | 277.47% |
| Mar 31, 2023 | -84.99% |
| Dec 31, 2022 | 287.65% |
| Sep 30, 2022 | -28.48% |
| Jun 30, 2022 | -23.82% |
| Mar 31, 2022 | 34.02% |
| Dec 31, 2021 | 35.95% |
| Sep 30, 2021 | 62.34% |
| Jun 30, 2021 | 32.96% |
| Mar 31, 2021 | 5.53% |
| Dec 31, 2020 | 16.20% |